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The radioopaque compounds used in diagnostic
radiology are variously referred to as dyes, agents,
media, or materials, but by all criteria they are ac-
tually drugs. They differ from most conventional
drugs in terms of "pharmacologic" activity. This
activity is so weak that they may be administered in
large doses. They are, however, subject to the same
factors as other drugs in regards to absorption, dis-
tribution, excretion, and metabolism, and they re-
semble other drugs as far as untoward side reac-
tions are concerned. Many of these reactions can
neither be reproduced nor satisfactorily studied ex-
perimentally. Hence, underlying mechanisms re-
main poorly understood.
In the present review, we consider, first, the pub-
lished case reports and, second, an analysis of vari-
ous proposed mechanisms of nephrotoxicity.
Uro graphic radiocontrast drugs (Uro-RCD)
In the mid fifties, new triiodinated derivatives of
benzoic acid replaced the older agents (which had
been principally iodopyracet and acetrizoate). At
present, the most commonly used Uro-RCD are the
sodium and meglumine salts of diatrizoate, iothala-
mate, metrizoate, and ioxitalamate. (Unless stated
to the contrary, this review refers to these "mod-
ern" compounds.) Originally used for excretory
urography, these have found a variety of other ap-
plications, the most important of which are angiog-
raphy and computerized tomography (CT). The
Uro-RCD have iodine at the 2, 4, and 6 positions;
the substituents at positions 3 and 5 vary slightly
from one compound to another. The Uro-RCD have
the following characteristics in common. (I) They
exist in biologic fluids principally as the anion be-
cause of the low pKa of the carboxyl group. (2)
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Their sodium and meglumine salts are highly sol-
uble in water. (3) The undissociated acids are lipid
insoluble and hence diffuse poorly across epithelial
barriers. (4) As a consequence, they are poorly ab-
sorbed from the gastrointestinal tract, are not reab-
sorbed by the renal tubule, are distributed within
the extracellular space, and do not gain access to
those intracellular sites at which more lipid soluble
compounds undergo metabolic alteration. (5) They
are not significantly bound to plasma proteins and
are hence freely filtered at the glomerulus. (6) In
some species, they are secreted by the renal tuble,
but this mechanism is not detectable in man or the
dog. (7) They are rapidly excreted in the urine as the
parent compound without metabolites. (8) A small
but variable fraction is excreted in the bile. (9) The
Uro-RCD are usually administered parenterally, ei-
ther intravenously or intraarterially, often as hyper-
osmotic solutions. (JO) Many of the immediate
physiologic effects can be attributed to the osmotic
load. (11) Plasma decay curves have an initial steep
slope involving redistribution and a less steep slope
determined by renal excretion, the latter with a t'/2
in normal man of about 2 hours [1-3].
Clinical picture of urographic neophrotoxicity
Uro-RCD may cause mild side effects and, less
frequently, serious adverse reactions. In the latter
category are included anaphylactoid reactions, car-
diac dysfunction, and nephrotoxicity. It is at first
surprising that the latter is not mentioned in a num-
ber of surveys that have been conducted by radiolo-
gists [4, 5]. This omission, however, can readily be
explained by the fact that the complications that
come to the attention of the radiologist are those
that occur during the actual procedure, or while the
patient is still in the x-ray department. The onset of
acute renal failure usually occurs after several
hours to days and, hence, in such surveys, has gone
undetected.
Nrphrotoxic i ty  of urogruphic d rugs  
Retrospective case reports may be seriously mis- 
leading for certain types of analysis. Nevertheless, 
as in the present situation, they may constitute the 
sole source of information. We have summarized 
the literature and have included 13 cases of our own 
(to be published in detail elsewhere). The greatest 
limitations to such a survey lie in the fact that the 
absence of a given factor receives equal significance 
whether it is specifically denied or just not men- 
tioned. We have focused on pharmacologic parame- 
ters and have excluded those complications that di- 
rectly result from the techniques of angiography or 
retrograde urography. Nevertheless, for the sake of 
completeness, it is noted that renal failure may re- 
sult from atheromatous emboli that are dislodged 
during angiography, and that initially this may clini- 
cally resemble renal impairment that is more direct- 
ly drug related. 
Nephrotoxicity has been attributed to the Uro- 
RCD when there has been a sudden change in renal 
status after the administration of the drug and no 
other etiology appeared likely from the clinical rec- 
ord. When serum creatinine was used as an index of 
renal function, we have included only those cases in 
which the level increased by a minimum of 1 mg/dl. 
In those relatively few cases in which only the 
blood urea was available, proportional increments 
have been accepted. Outcome has been scored as 
follows: I, eventual return of renal function to nor- 
mal, with serum creatinine not more than 0.5 mg/dl 
greater than that of control; 11, recovery, but with 
serum creatinine more than 0.5 mg/dl greater than 
that of control; and 111, death in uremia, or transfer 
to a program of chronic dialysis or transplantation. 
(Categories I and I1 include some cases with tempo- 
rary dialysis.) 
The major syndromes of nephrotoxicity are listed 
in Table 1. The chronology, which is depicted in 
Fig. 1 ,  considers all reported cases and illustrates 
several points of interest. From about 1955 to 1960, 
the newer triiodinated benzoates were introduced 
to clinical usage and replaced the older drugs. On 
the basis of animal studies, the newer agents were 
considerably less nephrotoxic [6]. The number of 
case reports, however, has rapidly increased, par- 
ticularly in the last 10 years. Although the total con- 
sumption of Uro-RCD has also risen sharply, it is 
not known whether the number of case reports is 
proportional to usage or dosage, or whether there 
has been an actual increase in the incidence of reac- 
tions. It is somewhat surprising that the associated 
disorders (Fig. 1) included a high incidence of mul- 
tiple myeloma (a fairly rare disease) prior to about 
Table 1. Major syndromes of nephrotoxicity following 
administration of modem Uro-RCD 
Number of cases 
Total Outcomea 
A. Reduced GFR, with oliguria 200 133 27 40 
A'. Reduced GFR, oliguria not known 31 25 5 1 
B. Reduced GFR, without oliguria 30 20 3 7 
C. Acute hypotension 2 2 0 0  
D. Sensitivity-like reaction 3 3 0 0  
E. Medullary necrosis 6 0 0 6  
F. Proteinuriab 12 12 0 0 
"Categories of outcome are: I, retum of renal function to nor- 
mal; 11, recovery but with partial diminution of renal function; 
and 111, death in uremia, or transfer to program of chronic dial- 
ysis or transplantation. (For further details, see text.) 
bIncludes only "massive" proteinuria as described by au- 
thors. 
1965, whereas since that time diabetes mellitus and 
heart disease have been increasingly noted. One 
wonders what factors in the older literature pre- 
cluded association with these common disorders. 
The relationship to age (Fig. 2) almost certainly re- 
Mult. myel. 
Diabetes 
Cardiac dis. or diuretics 
Diabetes + cardiac dis. 
Year 
Fig. 1 .  Chronology of nephrotoxic reactions to Uro-RCD as re- 
ported in the literature, types A-D, both old and modern drugs 
included. Year is date of publication. Summary limited to pa- 
tients individually identifiable in reports. For most cases, refer- 
ences are given in Ref. 63 and 114. 
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Q Type "A" 
Type"B" 
Day of peak Pa 
Age, yr 
Fig. 2 .  Relation of age to nephrotoxirity t o  Uro-RCD. 
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Peak rise PC,, mg/dl 
flects the incidence of radiologic procedures. Neph- 
rotoxicity may occur, however, in the youngest age 
group, and the aging process is thus not an essential 
etiologic factor. In the reported cases, males out- 
number females 1.8:l.O. For other adverse reac- 
tions to Uro-RCD, there was no detectable sex dif- 
ference [7]. 
The enormous variation in incidence undoubtedly 
depends on methodology. Older et a1 [8] found that 
the incidence varied from 0 to 2.8% in published re- 
ports, and then calculated a 10% incidence in their 
own series. But they defined deterioration of renal 
function as an increase in serum creatinine of either 
20% or 0.3 mg/dl. Using the criterion of a 1-mg/dl 
rise in serum creatinine, in two retrospective stud- 
ies of radiologic procedures, Swartz et a1 [9] found 
the incidence of renal impairment to be 12% after 
angiography, whereas vanZee et a1 [lo] found 0.8% 
after intravenous urography (IVP). 
Type A: Reduced Jiltration rate (GFR) with oli- 
guria. This is by far the most common clinical pat- 
tern. Oliguria or anuria usually develops within 24 
hours without other significant symptoms. The ex- 
act time of onset of oliguria, however, has rarely 
been reported. It should be emphasized that innu- 
Fig. 3. Response of plasma creatinine in acute rend failure of 
types A and B ,  modern Uro-RCD only. Patients undergoing dial- 
ysis or with multiple myeloma are excluded. 
merable case reports specifically deny the presence 
of signs or symptoms of hypersensitivity or the 
presence of an acute episode of hypotension. Re- 
duction in GFR is reflected by a rise in serum creati- 
nine, which most frequently reaches a peak on day 
3 with a mean increment of about 3 mg/dl (Fig. 3). 
Oliguria has usually been defined as urine volume of 
400 ml or less per day. Many cases of outright 
anuria have been described. In our 13 patients, the 
minimal daily urine output was on the average 120 
ml. 
The relationship of dose of Uro-RCD is summa- 
rized in Fig. 4 with data restricted to the modern 
drugs. It is readily apparent that renal failure can 
occur after the administration of doses that are in 
common usage. The question of multiple proce- 
dures is considered later. Diatrizoate, iothalamate, 
metrizoate, and ioxitalamate have all been impli- 
cated without any clear distinction between them. 
Likewise, there appears to be no difference be- 
tween the sodium and meglumine salts. 
Nephrotoxicity o f  urographic d rugs  
Uro-RCD dose, g of  iodine 
Fig. 4 .  Relationship of dose of Uro-RCD to renal failure, types A 
and B ,  modern drugs only. Summary limited to adult patients; 
doses originally reported per kilogram of body weight have been 
recalculated assuming 60 kg of body wt. 
Associated diseases or risk factors have received 
extensive attention since the first report by Bartels 
et a1 [ l l ]  on multiple myeloma. For summary pur- 
poses, we have grouped together under "cardiac 
disease" patients who had heart disease and/or 
were receiving diuretics (the latter includes 5 pa- 
tients with cirrhosis and without heart failure). This 
grouping seemed justified on the basis that the renal 
tubule would tend to completely reabsorb sodium 
chloride in the absence of diuretics in all such pa- 
tients, and that a low urinary chloride concentration 
might be associated with a high level of contrast 
drug in the urine [3]. Considering all cases of type A 
Table 2. Effect of associated diseases on outcome of type A 
nephrotoxicity with modem Uro-RCDa 
Average outcome 
All cases Control plasma 
creatinine 
Number 
Associated diseases of cases <5 >5 mgldl 
Multiple myeloma 9 2.9 - - 
Non-mult. myeloma: 
Diabetes Cardiac 
a For each subgroup, the average outcome was calculated by 
giving an arithmetic value of 1 ,  2, or 3 to each reported case in 
categories I, 11, or 111, respectively. 
nephrotoxicity, 66% have outcome I; 13%, outcome 
11; and 21%, outcome I11 (Table 1). But this distri- 
bution is markedly influenced by the associated risk 
factors, as indicated by the percentages of patients 
with outcome 111 (Table 2). The prognosis with mul- 
tiple myeloma is worse than it is with the other con- 
ditions and, incidentally, is the same with the mod- 
ern as with the older Uro-RCD. Considering the 
three variables of preexisting renal impairment, dia- 
betes, and cardiac disease, each appears to worsen 
the prognosis. The severity of renal impairment, as 
judged by final outcome, is the same with nonrenal 
angiography (28% outcome 111) as with IVP (26% 
outcome 111). The data are insufficient to determine 
whether with the modern drugs and dosage renal 
angiography produces a type of renal failure that is 
separate and distinct from that which follows non- 
renal angiography or i.v. urography . 
Data on the effect of these risk factors on the in- 
cidence of nephrotoxicity are somewhat sporadic. 
From six separate papers [12-171, a total of 508 
IVP's were recorded in patients with multiple 
myeloma of whom 5 developed acute renal failure. 
In several studies [18-211, the incidence in diabetics 
varied enormously, from virtually zero to almost 
100% depending on the degree of concomitant renal 
failure, which in turn is a function of the duration of 
the diabetes. No data are available on incidence in 
cardiac patients or in patients maintained on diuret- 
ics. The role of preexisting renal failure will be dis- 
cussed later. In the case of multiple myeloma, the 
available data suggest an unusual situation in which 
the incidence of nephrotoxicity is not unduly high 
but at the same time the prognosis is exceptionally 
poor. If valid, this phenomenon remains unex- 
plained. Greenberg [22] has urged the routine use of 
both the sulfosalicylic acid and "dip stick" tests for 
proteinuria prior to the administration of Uro-RCD, 
because a discrepancy between the two would sug- 
gest Bence-Jones protein and might lead to a diag- 
nosis of unsuspected myeloma. 
Type A': Reduced GFR, oliguria not specijied. 
Table 1 lists 31 cases with these characteristics. By 
available criteria, they appear indistinguishable 
from either type A or B. Because of the in- 
completeness of the data, they have not been in- 
cluded in the other summaries. 
Type B: Reduced GFR without oliguria. These 
cases are similar to type A except that oliguria is 
specifically denied. If one considers the pattern of 
the change in serum creatinine (Fig. 3), the dosage 
of Uro-RCD (Fig. 4), or the eventual outcome (Table 
l), there are no features that distinguish between 
Mudge 
types A and B. This also holds true for the associat- 
ed diseases. In type A, 21% of the patients had both 
diabetes and cardiac disease (Table 2) ,  whereas 
43% of type B had this combination. One is tempted 
to attribute the type B disorder to pre-existing renal 
disease, in which case oliguria might be masked by 
the obligatory polyuria of renal insufficiency. In 
support of this is the study of Millman and Gottleib 
[23] on 22 patients with chronic renal insufficiency 
in whom the creatinine clearance fell on the average 
by 23% by the second day after urography without 
concomitant oliguria. If one considers, however, all 
the reported cases, the control plasma creatinine in 
type B patients was 3.9 + (SD) 3.7 mgldl (N=28) ;  
this finding is not significantly different from type A, 
3 . 7  + (SD) 2.7 (N= 173). It is also possible that urine 
output could have been maintained by the excretion 
of greater than usual doses of contrast drug. This, 
however, does not appear to be the case, at least as 
judged by dosage (Fig. 4). 
Type C: Acute hypotension with renal failure. An 
unpredictable anaphylactic or vagal type of reaction 
is the most serious complication produced by con- 
trast agents. With severe hypotension, it is not sur- 
prising that renal failure may result. But despite the 
attention given to these reactions, the incidence of 
secondary renal failure has not been studied. Two 
possibilities arise: first, the anaphylactoid reaction 
itself might directly damage the kidney, and second, 
the combination of hypotension and high levels of 
contrast agent might be particularly nephrotoxic. 
Unfortunately, the published case reports do not 
provide a clear answer. Consider just the modern 
Uro-RCD. An immediate anaphylactoid reaction 
led to renal failure but with eventual complete re- 
covery in two instances [24-251. But in 20 patients 
who recovered from the immediate catastrophic re- 
action, either the oliguria persisted only as long as 
the hypotension, or if there was any change in renal 
function it was so trivial that it was not mentioned 
by the authors [25-331. In an animal model, the ad- 
ministration of Uro-RCD following 90 min of com- 
plete renal ischemia did not predispose to postur- 
ographic renal dysfunction or deleteriously affect 
recovery [34]. 
Type D: Sensitivity reactions without hypoten- 
sion. Whether this should be considered as a com- 
pletely separate category is uncertain. However, 
from the available data on two patients, there ap- 
peared to be no anaphylactoid shock; and in a total 
of three patients, the findings suggest a sensitivity 
reaction. The patient of Kleinknecht et  a1 [35] de- 
veloped bronchospasm and hypertension. Serum 
antibodies to iothalamate were identified that react- 
ed with various analogues of the contrast agent, in- 
dicating that the triiodinated benzene nucleus was 
essential for the antibody reaction. The patient of 
Borra et a1 [36] developed a maculopapular rash 
with eosinophilia. Renal biopsy showed prolifera- 
tive glomerulonephritis. No antibody to contrast 
agent could be detected in the serum. A third pa- 
tient developed proliferative glomerulonephritis af- 
ter diatrizoate [37]. In each instance, after the con- 
trast agent had been administered, the patient de- 
veloped acute renal failure with prolonged 
proteinuria but eventual complete recovery. 
Type E: Hemorrhagic medullary necrosis. Six 
cases have been reported in which this type of le- 
sion developed in infants. It has been speculated 
that anoxia may have been a contributing factor. No 
comparable lesions confined to the medulla have 
been described in adults; the underlying mechanism 
is not known [38]. 
Type F: Proteinuria. In their protonated form, the 
triiodobenzoates are water insoluble and form vis- 
ible precipitates. Hence, any test for urinary protein 
that requires the addition of acid may be falsely pos- 
itive in the presence of Uro-RCD. Undoubtedly, 
many of the reported instances of drug-related al- 
buminuria are of this nature. True albuminuria is 
not characteristic of type A or B nephrotoxicity, but 
does occur in type D; data for type C are in- 
adequate. With specific analytic methods, a tran- 
sient and sometimes massive proteinuria has been 
described after renal angiography [39-411. The vari- 
ability in the reported incidence is consistent with 
the postulated mechanism that for a brief moment 
Uro-RCD in the renal circulation achieves a critical 
concentration that alters glomerular capillary per- 
meability [42]. Such a mechanism is supported by 
the excretion of protein of high molecular weight (in 
addition to albumin) and by direct visualization of 
other capillary beds [40, 431. The albuminuria can 
be reproduced in experimental animals [44]. In the 
reported patients, there has been no concomitant 
oliguria or reduction in GFR or symptoms of hyper- 
sensitivity, although, in one patient, a more serious 
renal failure was associated with hypotension and a 
hematologic disorder. After IVP, a slight albumi- 
nuria is sometimes seen. In one case, the excretion 
of large amounts of albumin appeared to be ex- 
ceptional [45]. 
The following effects on the kidney or urinary 
tract warrant mention for completeness. 
Focal bullous edema of the bladder mucosa. This 
is a complication of retrograde pyelography in 
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which unusual sensitivity of the bladder or ureteral 
mucosa leads to obstruction and anuria [46]. The 
exact cause of the sensitivity is unknown. Its pos- 
sible reaction to the contrast agent within the urine 
has raised the possibility that it might also occur in 
response to Uro-RCD administered parenterally. In 
reported cases of renal failure following parenteral 
administration, subsequent cystoscopy failed to re- 
veal, however, any obstructive lesion of this type. 
Thus, it is extremely doubtful that this lesion is pro- 
duced by parenterally administered Uro-RCD. 
Extravasation o f  Uro-RCD into renal paren- 
chyma. This is a rare complication of the IVP, at- 
tributed to a sudden increase in intrapelvic pressure 
secondary to the osmotic diuresis induced by Uro- 
RCD that occurs in patients with ureteral obstruc- 
tion, most often due to renal calculi. Theoretically, 
this could also occur after angiography or CT scan. 
The Uro-RCD passes through a small tear in the cal- 
yceal fornix back into the renal sinus. Because the 
condition is accompanied by flank pain and hema- 
turia, it may mimic other renal disorders. It is not 
accompanied by renal failure in the usual sense, 
that is, oliguria or reduction in GFR. It should be 
distinguished from the more serious and far rarer 
tears in the ureter or pelvis [47]. The incidence was 
as high as 17% of patients with acute renal colic in 
one prospective study [48]. This high incidence is 
attributed to the increasingly large doses of Uro- 
RCD being used. 
Susceptibility t o  Uro-RCD following renal trans- 
plantation. The administration of Uro-RCD follow- 
ing transplantation is accompanied by a high in- 
cidence of allograft rejection [49]. This might pro- 
vide a useful experimental model for exploring 
immunologic aspects of toxicity. 
Mechanisms of urographic nephrotoxicity 
Because several different clinical syndromes may 
be distinguished, it is probable that a number of sep- 
arate mechanisms are involved. The possibility of 
hypersensitivity reactions with or without an immu- 
nologic basis has been mentioned above. The fac- 
tors discussed below are most relevant for renal 
failure of types A and B. 
Dose and concentration o f  Uro-RCD. In many 
pharmacologic situations, the concentration of drug 
at a receptor site is essentially proportional to the 
administered dose. Under many situations, this 
does not hold true for Uro-RCD. Besides dosage, 
one must consider the time after injection and the 
location or site in question. For example, with a 
bolus type of injection, the concentration in the re- 
nal artery is a function of the site of injection (pe- 
ripheral vein, heart, aorta, renal artery, and so 
forth), the concentration in the original preparation, 
the rate of injection, and the extent to which the 
injected volume is diluted by the time it reaches the 
kidney. In unpublished experiments in the dog, 
samples of femoral arterial blood were taken at 5- 
sec intervals after an angiographic type of injection. 
The initial peak concentrations indicated either a 
10- or 40-fold dilution depending on whether the in- 
jection was into the thoracic aorta or the brachial 
vein. Obviously, a bolus directly into the renal ar- 
tery would have been diluted to a lesser extent. 
These peak concentrations lasted 10 to 15 sec and 
then fell precipitously. Thereafter, the fall in plasma 
concentration involves both redistribution to the in- 
terstitial fluid and renal excretion. 
These dilution factors must also be considered in 
relation to changes in osmolality. Many authors 
have ascribed the nephrotoxic reactions to the ex- 
treme hypertonicity of the injected solutions. But 
with a large i.v. bolus of diatrizoate (which had an 
osmolality of 1490 mOsdkg),  the osmolality of pe- 
ripheral blood in the dog increased only from 292 to 
310 mOsdKg at 2 min and thereafter subsided (un- 
published observations). We also emphasize that 
the osmotic diuresis produced by Uro-RCD de- 
pends on the amount of nonreabsorbable solute de- 
livered to the nephron and not on any change in os- 
molality itself. For renal arteriography, no quan- 
titative data are available on the time course of the 
osmolality in the renal artery. 
The concentration of Uro-RCD in the tubular 
fluid and ultimately in the voided urine depends on 
complex interactions between a number of different 
physiologic factors [3] which include: (I) UV for 
Uro-RCD (where UV is the amount excreted per 
unit of time), which is determined both by GFR and 
the plasma level of Uro-RCD; (2) UV for all other 
urinary solutes, largely urea and sodium chloride, 
the latter being subject to greater variability as a re- 
sult of tubular reabsorptive activity; and (3) free- 
water production, which is influenced by anti- 
diuretic hormone but also by the rate of total solute 
excretion. For the present topic, we emphasize that 
there is no simple relationship between the adminis- 
tered dose and the urinary concentration of Uro- 
RCD. 
The concentration of drug in the renal paren- 
chyma or in the intraluminal fluid is probably more 
relevant to the question of nephrotoxicity than is 
the concentration in the voided urine. Although 
very little data are available, several physiologic 
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generalizations may be made. As to the intraluminal 
fluid, the concentration is intermediate between 
plasma and urine and rises progressively from the 
early proximal tubule to the late collecting duct. 
The action of antidiuretic hormone is principally on 
the collecting duct and distal convolution so that the 
effect of dehydration on intraluminal concentration 
is greatest in the distal nephron. For practical pur- 
poses, other factors remaining constant, there is 
probably no significant effect of mild dehydration 
on the tubular fluid concentration of drug at sites 
more proximal than the early distal tubule. 
Because the modem contrast agents do not un- 
dergo tubular reabsorption or secretion, one pre- 
sumes that they have the same intrarenal distribu- 
tion as inulin. Direct comparisons, however, are not 
available. The older Uro-RCD were secreted by the 
tubule and accumulated within the kidney, presum- 
ably intracellularly, either by active transport or 
binding [50]. Several observations, however, raise 
the question whether the modem Uro-RCD might 
gain limited access to the cells of the tubule. First, 
in some mammalian species, diatrizoate is secreted 
by the organic acid transport system of the proximal 
tubule [51]. By available clearance techniques, 
there is no convincing evidence for similar secretion 
in man or the dog, but whether there is a slight de- 
gree of undetectable transport is unanswerable. 
Second, diatrizoate inhibits the tubular transport of 
PAH in the dog [52] and of uric acid in man [53, 541. 
Usually such an interaction between organic acids 
is attributed to inhibition of transport in a more or 
less competitive manner. This implies that the two 
compounds both participate in the transport proc- 
ess. This, however, may not necessarily indicate 
that diatrizoate gains access to the intracellular 
space. Diatrizoate is reversibly bound to the periph- 
ery of the proximal and the luminal border of the 
distal tubule [55]. It is conceivable that similar bind- 
ing to proximal tubular membranes might affect the 
tubular transport of other compounds. Third, 
changes in tubular permeability may occur. These 
changes are considered below. 
Dehyctmtion. Interest in the possible role of de- 
hydration dates from the purposeful restriction of 
fluids, introduced in the early days of urography. 
Probably no contributory factor has been more 
widely discussed in the literature. Its exact role is 
difficult to evaluate. Although there are a number of 
patients who were undoubtedly severely dehy- 
drated at the time of urography [56, 571, the vast 
majority of reports are too imprecise to permit eval- 
uation. Theoretically, the single most valuable mea- 
surement would be the osmolality of the urine taken 
immediately prior to and following the radiologic 
procedure. Such data are not available. Even in 
their absence, one point may be made, namely that 
adequate hydration does not necessarily protect 
against type A nephrotoxicity. From the case re- 
ports, at least six instances of nephrotoxicity oc- 
curred in patients in whom purposeful hydration 
had been deemed adequate [18,58-601. In addition, 
in diabetics, the development of renal failure was 
unrelated to the state of hydration as measured by 
changes in body weight [19]. In a very recent study 
of angiography [6 11, the question of hydration was 
reexamined with the suggestion that the degree of 
hydration used in previous studies was insufficient. 
It has been tacitly assumed that the deleterious 
effects of dehydration are mediated by undesirably 
high concentrations of Uro-RCD achieved first 
within the tubular fluid, and subsequently in the 
urine. Direct supporting evidence is not available. 
From the clinical descriptions, except in very ex- 
ceptional cases, dehydration of a degree sufficient 
to compromise cardiac output and renal blood flow 
is not at issue. 
Prior and repeated doses.  It has often been said 
that the risk of nephrotoxicity is directly related to 
the frequency of radiologic examinations [62]. The 
issue can be subdivided into several different ques- 
tions. (1)  Dosage. There are two possibilities: first, 
the number of injections would tend to determine 
total dosage; and on this basis, one might expect 
some correlation between the frequency of toxicity 
and of procedures; or second, repeated doses might 
predispose to reactions so that the incidence of tox- 
icity after a second dose would be higher than it 
would be after the first dose. Unfortunately, the 
clinical documentation of incidence is not adequate 
to evaluate these possibilities. (2) Sensitivity. In 
types C and D, it might be postulated that patients 
had been sensitized by prior exposure. There was, 
however, no evidence that this was the case in the 
five patients summarized in Table 1. In type A, 
without clinical evidence of hypersensitivity, there 
are 18 patients reported with prior exposure to 
urographic agents and 182 (arteriography, 50; IVP 
or CT scan, 132) in which such exposure is either 
denied or not stated. The conclusion seems in- 
escapable that the urographic agents may be neph- 
rotoxic in a single dose. In the same reports, there 
are a number of instances in which the Uro-RCD 
were administered for a second time following the 
initial occurrence of type A renal failure. In three 
patients, this resulted in a separate and distinct epi- 
sode of renal failure. In the second episode, for one 
patient, clinical manifestations of hypersensitivity 
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are specifically denied [59]; for the other two, there 
are no relevant statements [lo, 621. In at least four 
patients [56], there was, however, no recurrent tox- 
icity with the second exposure to Uro-RCD. (3) Ra- 
diographic procedure. Arteriography is usually per- 
formed with repeated small doses of Uro-RCD in- 
jected with great rapidity into selected arteries. On 
the other hand, in IVP a single dose is usually ad- 
ministered with moderate rapidity as  a bolus, or 
more slowly by infusion. The latter method applies 
also to CT scans. For the same total dose, the angi- 
ographic procedure would produce the far most 
abrupt change in the plasma concentration to which 
the kidney is exposed. But from the clinical data, it 
is not possible to evaluate the significance of these 
procedural differences for nephrotoxicity. In the 
survey of the complications of abdominal arteri- 
ography made by McAfee [64], renal complications 
were attributed to the excessively high concentra- 
tions of Uro-RCD that were achieved either in the 
renal artery or  in the nearby aorta. This was with 
the older agents. For the modern ones, there are no 
comparable data. Experimentally, it is possible to 
produce renal failure with massive doses injected 
into the renal artery [65]. There is, however, no evi- 
dence that this is the counterpart of the nephrotox- 
icity described in most clinical reports, with the ex- 
ception of the rare case of accidental massive over- 
dosage [66]. As to the question of repeated doses, 
with the intraaortic injection of iothalamate, the in- 
cidence of azotemia is increased if the dose is re- 
peated at 15 min but not at a longer interval. This is 
not observed with diatrizoate [67]. It is not known 
whether this phenomenon has a clinical counter- 
part. 
Nephrogrum and pyelogram. The normal se- 
quence of events in renal or  aortic arteriography in- 
cludes an early dense renal shadow that appears 
within seconds and then rapidly subsides. This is 
associated with the acute peak blood concentration 
of Uro-RCD; it is not seen with the usual intra- 
venous procedure. Within a few minutes after either 
intraarterial or i.v. injection, the renal shadow then 
becomes progressively dense. This is the normal 
nephrogram. It is associated with the maximal 
amount of Uro-RCD within the tubular fluid. As the 
nephrogram subsides, approximately 10 min after 
injection, the pyelogram then increases in intensity. 
An abnormally dense and/or persistent nephro- 
gram may be produced by two separate mecha- 
nisms. First, in acute tubular necrosis, an immedi- 
ate dense nephrogram may appear. This is due to an 
increased permeability of the tubular epithelium to 
the contrast agent so that its volume of distribution 
within the kidney becomes greater than normal [68]. 
The pattern is seen in acute tubular necrosis from a 
variety of causes; it has not been reported in renal 
failure induced by the contrast agent itself. Second, 
an abnormally dense nephrogram may develop in 
any condition in which, with normal tubular per- 
meability, the rate at which contrast agent is deliv- 
ered into the tubular fluid exceeds the rate at which 
it is excreted into the pelvis and ureter. This can 
occur under two conditions: first, in acute hypoten- 
sion, when a small amount of residual glomerular 
filtration is accompanied by severe oliguria; and 
second, with either intra- or  extra-renal obstruc- 
tion, in which filtration persists and the on-going 
tubular reabsorption of water increases the concen- 
tration of nonreabsorbable solute (including Uro- 
RCD) within the tubular fluid. 
In patients with acute hypotension induced by 
urographic drugs, there is an early dense nephro- 
gram, which may promptly disappear as the hypo- 
tension is corrected and normal urine flow is rees- 
tablished [37, 311. An abnormal nephrogram more 
commonly occurs in type A nephrotoxicity. In the 
early descriptions of patients with multiple myelo- 
ma, it was clearly recognized that opacification of 
the renal pelvis, ureter, and bladder was initially 
normal. This indicated normal urinary excretory 
function; anuria did not develop until some time lat- 
er. Berdon et a1 [56] observed that the subsequent 
development of anuria was accompanied by the ap- 
pearance of a dense nephrogram. They attributed 
this to an intraluminal blockade resulting from the 
interaction between Uro-RCD and Tamm-Horsfall 
protein (see below). Older [69] reemphasized the di- 
agnostic significance of a late (24-hour) nephrogram 
and suggested that this might be the most sensitive 
index of Uro-RCD-induced renal failure. Because a 
late radiologic examination is not routine, the fre- 
quency of the late nephrogram is unknown. In our 
series of 13 patients, we happen to have four in- 
stances of a normal early pyelogram associated with 
a late dense nephrogram. All of our patients had oli- 
guria without anuria. The evidence strongly sug- 
gests that in oliguric type A renal failure a major 
portion of the nephrons gradually become tempo- 
rarily completely obstructed. Linear densities ob- 
served in the renal papilla in renal failure after cho- 
langiography were thought to represent intraluminal 
precipitation of iodipamide within the collecting 
ducts [69]. It is important to ascertain whether simi- 
lar shadows occur with urographic agents. 
Tubular blockade. Theoretically, this could result 
from (1) the precipitation of Uro-RCD itself, (2) an 
action of Uro-RCD to increase the tubular fluid con- 
Mudge 
Type "A" Type  "B" 
centration of another solute that is sparingly sol- 
uble, or (3) an interaction between Uro-RCD and 
some other component of the urine. The salts of 
Uro-RCD are extremely soluble, and there is no 
evidence that the limits of solubility could be ex- 
ceeded within the tubular fluid. As to other urinary 
solutes, the uricosuric action of Uro-RCD [53, 541 
raises the possibility that type A toxicity might be a 
manifestation of obstructive urate nephropathy. 
The evidence for this is extremely scanty. Presum- 
ably, if such a mechanism were operative, the de- 
gree of renal failure would be increased by hyper- 
uricemia. Figure 5 summarizes the available data. 
There is no correlation between plasma urate, the 
presence or absence of oliguria, and the eventual 
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There is considerable evidence that the inter- 
action between Uro-RCD and Tamm-Horsfall (TH) 
protein may produce an obstructive nephropathy. 
TH is a mucoprotein of high molecular weight, that 
aggregates to form gels. It is the major constituent 
of urinary casts [71] including those seen in multiple 
myeloma. It is synthesized within the kidney by the 
cells of the ascending limb of the loop of Henle and 
of the macula densa segment of the distal tubule [72, 
731. TH is a normal urinary component, but its ex- 
cretion may increase with acute renal lesions [74]. 
TH is normally detectable within the cells and the 
adjacent tubular lumen, but with severe tubular 
damage it may migrate to the renal interstitium [75]. 
The precipitation of TH is enhanced by a low pH 
and high salt concentration. The formation of TH 
gels is also facilitated by serum albumin [71], 
Bence-Jones protein [71], and the modern Uro- 
RCD [76]. In type A renal failure, recovery from the 
oliguric phase may be accompanied by increased 
excretion of casts and TH [56]. These findings led to 
the proposal that Uro-RCD might react with TH 
within the tubular fluid, thus leading to precipitation 
of TH, cast formation, and intrarenal obstruction 
[56, 761. Such a mechanism is consistent with the 
sequential changes in the pyelogram and nephro- 
gram described above. It is also consistent with 
both the natural history and anatomic findings of 
Uro-RCD-induced renal failure in multiple myelo- 
ma. In this condition the reaction between Uro- 
RCD and TH might also be facilitated. by the pres- 
ence of Bence-Jones protein. Because small 
amounts of TH are excreted by the normal kidney, 
it is possible that precipitates of TH and Uro-RCD 
might also underly type A nephropathy in patients 
without multiple myeloma. To this mechanism, it 
should now be added that in the rare instance that 
Uro-RCD induces proteinuria this also would en- 
hance TH precipitation. 
Renal bloodjow and ischemia. Despite repeated 
statements to the contrary, there is little evidence 
that ischemia is the mechanism by which urograph- 
ic agents produce renal failure. Most experimental 
studies have mimicked arteriography rather than in- 
travenous procedures. In the parameters that have 
been studied, there have been either no changes or 
transient ones of only minor magnitude. This ap- 
plies to filtration rate [77-791, intrarenal redistribu- 
tion of blood flow [80-821, and tissue anoxia and 
changes in oxyhemoglobin dissociation [83, 841. 
The angiographically induced biphasic changes in 
renal blood flow are far too transient to produce is- 
chemic damage [82, 85-87]. In the evaluation of the 
role of hypertonicity itself, the variable findings ap- 
pear to depend on the exact experimental condi- 
tions [88-891. It has also been suggested that 
changes in viscosity and erythrocyte aggregation 
might adversely affect the renal microcirculation 
[90-911. It should also be kept in mind that Uro- 
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der some conditions may increase intraluminal 
pressure with secondary effects on filtration and 
possibly blood flow [92]. From the clinical data pre- 
viously cited, two observations argue against an is- 
chemic mechanism: first, that early in type A failure 
the excretory pyelogram is typically normal, im- 
plying that filtration is unimpaired; and second, that 
there are many instances in which a severe episode 
of hypotension failed to evolve into renal failure. 
Tubular function. Although Uro-RCD may affect 
several different renal tubular functions [52-54, 931, 
there is no evidence that these actions are directly 
deleterious. The tubule is normally impermeable to 
the modern Uro-RCD in man. If permeability were 
to increase, the drugs might have a different effect 
on the tubular cell. With increased intrarenal pres- 
sure, iothalamate is reabsorbed to a slight extent, 
but whether it is by an intercellular or an intra- 
cellular route is not known [94]. The Uro-RCD also 
produce enzymuria, suggesting altered cellular per- 
meability [95-981. When diatrizoate was adminis- 
tered to animals in which acute renal failure had 
been previously produced by either glycerol, mer- 
curic cholide, ischemia, or hydronephrosis, there 
was no increase in apparent renal damage [99-1001 
except at high dosage [ lol l .  In acute renal failure in 
man, the diagnostic use of IVP has been advocated 
[102, 1031. This appears not to influence outcome 
adversely. 
Associated diseases. The physiologic basis for 
the apparent increased risk in patients with diabetes 
or congestive heart failure is uncertain. Although 
underlying vascular disease has been incriminated, 
a mechanism by which such lesions might ex- 
acerbate toxicity to the kidney is not known. In the 
case of chronic renal failure, the early use of the 
modern Uro-RCD in high doses was accompanied 
by five instances of renal functional deterioration in 
90 patients, four of which were transient [104]. Sub- 
sequent prospective studies have been conflicting. 
Considering both angiography and urography, and 
judging renal function by the plasma creatinine andl 
or creatinine clearance, investigators found no ad- 
verse effect in a total of 283 patients [105-1091, but 
in another set of reports totaling 482 patients, inves- 
tigators observed frequently a decreased renal func- 
tion [lo, 19, 20, 22, 110-1 121. In the former studies, 
observations were made at less frequent intervals 
than in the latter, and it is quite probable that a tran- 
sient effect was overlooked. The most commonly 
observed pattern is a rise in plasma creatinine, 
peaking from day 2 to 4 and thereafter subsiding, 
without concomitant oliguria (that is, type B). 
It may be noted that in 78 reported cases the rise 
in BUN is relatively far less than that of creatinine. 
The mean increments are 8 mg/dl for BUN per 1 mg/ 
dl of creatinine. This is a smaller ratio than for other 
types of acute renal failure and applies to both types 
A and B, with or without prior renal disease. Con- 
sidering the mechanisms of excretion of creatinine 
and urea, this might represent complete blockade of 
some nephrons with diuresis in others. 
Pathology. In multiple myeloma, a characteristic 
lesion consists of dense tubular casts that produce 
obstruction (see above discussion of TH protein). 
In type D, several biopsies have shown proliferative 
glomerulonephritis. With these exceptions, the pa- 
thology of Uro-RCD-induced renal failure is for the 
most part unknown. Sporadic cases are difficult to 
evaluate because of the enormous variations in time 
interval, and also because of the brevity of the his- 
tologic descriptions themselves. In the only system- 
atic study available, Moreau et a1 [I131 performed 
biopsies a short time after urography or renal arteri- 
ography and found histologic lesions of "osmotic 
nephrosis" in 22% of their patients. This lesion con- 
sists of an intense vacuolization of the cytoplasm of 
the cells of the proximal tubule. There was a posi- 
tive correlation between the extent of the lesion and 
either the amount of Uro-RCD injected or the de- 
gree of prior renal impairment, but there was no 
parallelism between the lesion and any change in 
the serum creatinine or urine volume following radi- 
ography. Hence, the morphologic changes under- 
lying the nephrotoxicity induced by these agents re- 
main unknown. 
Summary. Nephrotoxicity of Uro-RCD is seen in 
only a very small fraction of the patients to whom 
the drugs are administered, and for most but not all 
patients, the toxicity is quite mild and followed by 
complete recovery. Although not reviewed here, 
the picture is significantly different from that pro- 
duced by another type of radioopaque agent, the 
cholecystographic drugs, and the two should not be 
confused. The shortcomings of retrospective clini- 
cal case reports are all too obvious, particularly in 
dealing with incidence and mechanism. On clinical 
grounds, there is, however, adequate reason to be- 
lieve that several different mechanisms may be in- 
volved. When angiography was introduced, the use 
of these drugs increased enormously. The same will 
undoubtedly happen with the growth of CT scans. 
Although the evidence is overwhelming that tox- 
icity is real, and although the incidence is apt to in- 
crease with greater usage, both the nature and the 
magnitude of the problem remain uncertain, partic- 
Mudge 
ularly when considered in relation to the larger is- 
sues of diagnostic medicine in general. Further in- 
sight can only be achieved by prospective studies 
purposefully directed to the issue of nephrotoxicity 
itself. 
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